Steven Cohen Janux Therapeutics, Inc. Transaction History
Point72 Asset Management, L.P.
- $42.2 Billion
- Q4 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 621,383 shares of JANX stock, worth $19.2 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
621,383
Previous 395,875
56.96%
Holding current value
$19.2 Million
Previous $18 Million
84.99%
% of portfolio
0.08%
Previous 0.05%
Shares
3 transactions
Others Institutions Holding JANX
# of Institutions
229Shares Held
55.2MCall Options Held
687KPut Options Held
357K-
Ra Capital Management, L.P. Boston, MA10.4MShares$320 Million8.99% of portfolio
-
Janus Henderson Group PLC London, X03.56MShares$110 Million0.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.52MShares$109 Million7.18% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.06MShares$94.6 Million0.3% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$72.5 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.29B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...